期刊文献+

深圳市南山区2006-2012年丙型肝炎流行病学特征分析 被引量:2

The epidemiological study on hepatitis C epidemic situation in Nanshan district of Shenzhen during 2006 to 2012
原文传递
导出
摘要 摘要:目的掌握深圳市南山区2006-012年丙型肝炎流行特征,提出科学防控策略。方法采用描述性流行病学分析方法,对《中国疾病预防控制信息系统》中报告的深圳市南山区2006-2年丙型肝炎发病数据进行统计分析。结果2006-2012年丙肝发病676例,发病率呈上升趋势。发病无明显季节性,男女发病比例约为1.40:1,发病年龄集中在40~60岁。结论丙肝发病呈上升趋势,应引起足够重视,在无疫苗的情况下,加大对吸毒人群的干预和健康教育仍是重要的防控措施。 Objective To analyze the epidemiological characteristics of hepatitis C in Nanshan district of Shenzhen in 2006-2012,and provide scientific control strategy. Method The reported epidemic data of hepatitis C in Nanshan district of Shenzhen during 2006-2012 were collected from the China Diseases Prevention and Control Information System, and statistically analyzed with descriptive epidemiological methods. Results Totally 676 cases were reported in Nanshan district of Shenzhen from 2006 to 2012. The incidence rate of hepatitis C was in an ascending trend. There was no seasonal character. Most of them were in the age group of 40-60 years old. The ratio of male to female was 1.40:1. Conclusion The situation of hepatitis C in Nanshan district is serious, so we should take specific intervene measures to reduce the incidence of hepatitis C.
出处 《热带医学杂志》 CAS 2013年第12期1539-1540,1552,共3页 Journal of Tropical Medicine
关键词 病毒性肝炎 丙型肝炎 流行病学 viral hepatitis hepatitis C epidemiology
  • 相关文献

参考文献3

二级参考文献25

  • 1符剑,李倩,蒋征刚,胡芳芳,陆烨.浙江省丙型肝炎血清流行病学调查[J].浙江预防医学,2004,16(8):26-27. 被引量:10
  • 2倪燕君,刘厚钰.职业性血源危害的危险性评估和处理(乙型肝炎和丙型肝炎)[J].肝脏,2004,9(2):116-117. 被引量:1
  • 3Ciesek S, Steinmann E, Wedemeyer H, et al. Cyclosporine A inhibits hepatitis C virus nonstructural protein through cyclophilin A[J]. Hepatology ,2009, 50(5) : 1638-1645.
  • 4Martinez-Donato G, Musacchio A, Alvarez-Lajonchere L, et al. Ratio of HCV structural antigens in protein-based vaccine formulations is critical for functional immune response induction [J]. Biotechnol Appl Biochem, 2010,56(3) : 111-118.
  • 5Buonaguro L, Petrizzo A, Tornesello M, et al. Immunesignatures in human PBMCs of idiotypic vaccine for HCV-related lymphoproliferative disorders [J]. J Transl Med, 2010, 19 (10) : 8-18.
  • 6Leroux-Roels G, Depla E, Hulstaert F, et al. A candidate vaccine based on the hepatitis C E1 protein : tolerability and immuneogenicity in heahhy volunteers [ J ]. Vaccine, 2004, 22 ( 11 ) : 3080-3086.
  • 7Sallberg M, Frelin L, Weiland O. DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving target[J]. Expert Opin Biol Ther,2009, 9(7) : 805-815.
  • 8Zhu Q, Guo Jr, Seeger C. Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells [J]. J Virol, 2003, 77( 12): 9204-9210.
  • 9Lagging LM, Meyer K, Hoft D, et al. Immune responses to plasmid DNA encoding the hepatitis C virus core protein [J]. J Viml, 2005, 69(9) : 5859-5863.
  • 10Rollier C, Depla E, Drexhage JA, et al. Control of heterolozous hepatitis C virus infection in chimpanzees is associated with the quality of vaccine induced peripheral T-helper immune response [J]. J Virol, 2004, 78(6) : 187-196.

共引文献30

同被引文献30

引证文献2

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部